Paclitaxel-Succinic acid

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 620101

CAS#: 117527-50-1

Description: Paclitaxel-Succinic acid, also known as Paclitaxel Succinate or Paclitaxel-hemisuccinic acid, is a paclitaxel derivative with a succinic acid linker. The carboxy group of Paclitaxel-Succinic acid, after activiating, can be used to conjugate with other molecules such as peptides, proteins, antibodies or enzymes, or polymers. Paclitaxel-Succinic acid is a useful agent to make Paclitaxel-conjugate for drug delivery, nanodrug research.

Price and Availability


USD 150
USD 750

USD 250
USD 1250

USD 450
USD 2950

Paclitaxel-Succinic acid, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 2g may be 6 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 620101
Name: Paclitaxel-Succinic acid
CAS#: 117527-50-1
Chemical Formula: C51H55NO17
Exact Mass: 953.347
Molecular Weight: 953.991
Elemental Analysis: C, 64.21; H, 5.81; N, 1.47; O, 28.51

Related CAS #: 33069-62-4   117527-50-1    

Synonym: Paclitaxel-Succinic acid; Paclitaxel Succinate; Paclitaxel-hemisuccinic acid.

IUPAC/Chemical Name: 4-(((1S,2R)-1-benzamido-3-(((2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-diacetoxy-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-9-yl)oxy)-3-oxo-1-phenylpropan-2-yl)oxy)-4-oxobutanoic acid


InChi Code: InChI=1S/C51H55NO17/c1-27-33(66-47(62)41(67-37(58)23-22-36(56)57)39(30-16-10-7-11-17-30)52-45(60)31-18-12-8-13-19-31)25-51(63)44(68-46(61)32-20-14-9-15-21-32)42-49(6,34(55)24-35-50(42,26-64-35)69-29(3)54)43(59)40(65-28(2)53)38(27)48(51,4)5/h7-21,33-35,39-42,44,55,63H,22-26H2,1-6H3,(H,52,60)(H,56,57)/t33-,34-,35+,39-,40+,41+,42-,44-,49+,50-,51+/m0/s1

SMILES Code: [H][C@@]1([C@@H]([C@@](C2(C)C)(C[C@@H](C(C)=C2[C@H](C([C@]([C@H](C[C@]34[H])O)1C)=O)OC(C)=O)OC([C@@H]([C@H](C5=CC=CC=C5)NC(C6=CC=CC=C6)=O)OC(CCC(O)=O)=O)=O)O)OC(C7=CC=CC=C7)=O)[C@@]3(CO4)OC(C)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Yan Q, Yang Y, Chen W, Hu J, Yang D. Construction of polymer-paclitaxel conjugate linked via a disulfide bond. Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:580-5. doi: 10.1016/j.msec.2015.09.025. Epub 2015 Sep 10. PubMed PMID: 26478347.

2: Yin S, Huai J, Chen X, Yang Y, Zhang X, Gan Y, Wang G, Gu X, Li J. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 2015 Oct 15;26:274-85. doi: 10.1016/j.actbio.2015.08.029. Epub 2015 Aug 20. PubMed PMID: 26300335.

3: He X, Lin M, Lu T, Qu Z, Xu F. Molecular analysis of interactions between a PAMAM dendrimer-paclitaxel conjugate and a biomembrane. Phys Chem Chem Phys. 2015 Nov 28;17(44):29507-17. doi: 10.1039/c5cp02242h. Epub 2015 Aug 10. PubMed PMID: 26256278.

4: Wu D, Zheng Y, Hu X, Fan Z, Jing X. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model. Mater Sci Eng C Mater Biol Appl. 2015 Aug;53:68-75. doi: 10.1016/j.msec.2015.04.012. Epub 2015 Apr 14. PubMed PMID: 26042692.

5: Du AW, Lu H, Stenzel MH. Core-Cross-Linking Accelerates Antitumor Activities of Paclitaxel-Conjugate Micelles to Prostate Multicellular Tumor Spheroids: A Comparison of 2D and 3D Models. Biomacromolecules. 2015 May 11;16(5):1470-9. doi: 10.1021/acs.biomac.5b00282. Epub 2015 Apr 17. PubMed PMID: 25857405.

6: Ma P, Zhang X, Ni L, Li J, Zhang F, Wang Z, Lian S, Sun K. Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab. Int J Nanomedicine. 2015 Mar 18;10:2173-90. doi: 10.2147/IJN.S77152. eCollection 2015. PubMed PMID: 25834432; PubMed Central PMCID: PMC4370923.

7: Peng L, Schorzman AN, Ma P, Madden AJ, Zamboni WC, Benhabbour SR, Mumper RJ. 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model. Int J Nanomedicine. 2014 Jul 30;9:3601-10. doi: 10.2147/IJN.S66040. eCollection 2014. PubMed PMID: 25114529; PubMed Central PMCID: PMC4124067.

8: Oyama T, Takeuchi H, Matsuda S, Ozawa S, Kitajima M, Kitagawa Y. Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-Paclitaxel conjugate. Anticancer Res. 2014 Apr;34(4):1751-7. PubMed PMID: 24692706.

9: Caron J, Maksimenko A, Wack S, Lepeltier E, Bourgaux C, Morvan E, Leblanc K, Couvreur P, Desmaële D. Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene. Adv Healthc Mater. 2013 Jan;2(1):172-85. doi: 10.1002/adhm.201200099. Epub 2012 Dec 4. PubMed PMID: 23213041.

10: Ma P, Rahima Benhabbour S, Feng L, Mumper RJ. 2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. Cancer Lett. 2013 Jul 1;334(2):253-62. doi: 10.1016/j.canlet.2012.08.009. Epub 2012 Aug 16. PubMed PMID: 22902506; PubMed Central PMCID: PMC3522796.

11: Liang L, Lin SW, Dai W, Lu JK, Yang TY, Xiang Y, Zhang Y, Li RT, Zhang Q. Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity. J Control Release. 2012 Jun 28;160(3):618-29. doi: 10.1016/j.jconrel.2012.02.020. Epub 2012 Mar 3. PubMed PMID: 22410114.

12: Wang Z, Hu X, Yue J, Jing X. Experimental study on biodegradable polymer-paclitaxel conjugate micelles for chemotherapy of C6 glioma. J Control Release. 2011 Nov 30;152 Suppl 1:e41-2. doi: 10.1016/j.jconrel.2011.08.110. PubMed PMID: 22195914.

13: Yang D, Van S, Liu J, Wang J, Jiang X, Wang Y, Yu L. Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment. Int J Nanomedicine. 2011;6:2557-66. doi: 10.2147/IJN.S25044. Epub 2011 Oct 21. PubMed PMID: 22072890; PubMed Central PMCID: PMC3205149.

14: Galer CE, Sano D, Ghosh SC, Hah JH, Auzenne E, Hamir AN, Myers JN, Klostergaard J. Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol. 2011 Nov;47(11):1039-47. doi: 10.1016/j.oraloncology.2011.07.029. Epub 2011 Sep 7. PubMed PMID: 21903450.

15: Li S, Gray BP, McGuire MJ, Brown KC. Synthesis and biological evaluation of a peptide-paclitaxel conjugate which targets the integrin αvβ₆. Bioorg Med Chem. 2011 Sep 15;19(18):5480-9. doi: 10.1016/j.bmc.2011.07.046. Epub 2011 Aug 4. PubMed PMID: 21868241; PubMed Central PMCID: PMC3195361.

16: Wan Y, Zheng Y, Song X, Hu X, Liu S, Tong T, Jing X. Anti-tumor activity of biodegradable polymer-paclitaxel conjugate micelles on Lewis lung cancer mice models. J Biomater Sci Polym Ed. 2011;22(9):1131-46. doi: 10.1163/092050610X500570. PubMed PMID: 20594407.

17: Zhang SQ, Song YN, He XH, Zhong BH, Zhang ZQ. Liquid chromatography-tandem mass spectrometry for the determination of paclitaxel in rat plasma after intravenous administration of poly(L-glutamic acid)-alanine-paclitaxel conjugate. J Pharm Biomed Anal. 2010 Apr 6;51(5):1169-74. doi: 10.1016/j.jpba.2009.11.030. Epub 2009 Dec 4. PubMed PMID: 20036092.

18: Chun C, Lee SM, Kim SY, Yang HK, Song SC. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials. 2009 Apr;30(12):2349-60. doi: 10.1016/j.biomaterials.2008.12.083. PubMed PMID: 19178941.

19: Ryppa C, Mann-Steinberg H, Biniossek ML, Satchi-Fainaro R, Kratz F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int J Pharm. 2009 Feb 23;368(1-2):89-97. doi: 10.1016/j.ijpharm.2008.09.055. Epub 2008 Oct 17. PubMed PMID: 18992308.

20: Lee H, Lee K, Park TG. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem. 2008 Jun;19(6):1319-25. doi: 10.1021/bc8000485. Epub 2008 May 16. PubMed PMID: 18481885.